A new option for therapeutic management of patients with cardiovascular disease: A closer look at the ONTARGET study

Research output: Contribution to journalArticle

Abstract

Therapeutic strategy aimed at global cardiovascular risk reduction represents a key priority for any prevention strategy, as clearly stated in the most recent international guidelines. In this view, therapeutic strategies based on ACE inhibitors have been demonstrated to significantly reduce cardiovascular morbidity and mortality in high-risk individuals. In the last decade, a long debate has developed in the scientific and medical community over whether the newer classes of antihypertensive agents, such as angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), have additional properties beyond blood pressure control, and therefore are superior to ACE inhibitors in terms of cardiovascular prevention. ARBs have been extensively investigated in a number of clinical conditions across the whole continuum of cardiovascular renal diseases, and these studies have prompted the use of these compounds as a first-line treatment for hypertension, as well as a treatment of choice in diabetic patients with nephropathy. The recently published ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) study, performed in a vast population of individuals at high risk, has challenged this substantially exclusive indication of ACE inhibitors, and namely of ramipril, by testing the non-inferiority of the ARB telmisartan and the hypothesis of a superiority of the combination of ramipril plus telmisartan compared with monotherapy with ramipril alone. The results of this study demonstrated that telmisartan was substantially equivalent to ramipril in high-risk patients in terms of cardiovascular protection, while the combination of the two drugs was associated with more adverse events without an increase in cardiovascular benefit.

Original languageEnglish
Pages (from-to)47-51
Number of pages5
JournalHigh Blood Pressure and Cardiovascular Prevention
Volume15
Issue number2
DOIs
Publication statusPublished - 2008

Fingerprint

Ramipril
Cardiovascular Diseases
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II Type 1 Receptor Blockers
Therapeutics
Drug Combinations
Risk Reduction Behavior
Antihypertensive Agents
telmisartan
Guidelines
Blood Pressure
Hypertension
Morbidity
Kidney
Mortality
Population

Keywords

  • ACE inhibitors
  • Angiotensin II receptor blockers
  • Cardiovascular mortality
  • Cardiovascular risk
  • Clinical trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{85ab00f805224554aa8cf53e7c5f0fcb,
title = "A new option for therapeutic management of patients with cardiovascular disease: A closer look at the ONTARGET study",
abstract = "Therapeutic strategy aimed at global cardiovascular risk reduction represents a key priority for any prevention strategy, as clearly stated in the most recent international guidelines. In this view, therapeutic strategies based on ACE inhibitors have been demonstrated to significantly reduce cardiovascular morbidity and mortality in high-risk individuals. In the last decade, a long debate has developed in the scientific and medical community over whether the newer classes of antihypertensive agents, such as angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), have additional properties beyond blood pressure control, and therefore are superior to ACE inhibitors in terms of cardiovascular prevention. ARBs have been extensively investigated in a number of clinical conditions across the whole continuum of cardiovascular renal diseases, and these studies have prompted the use of these compounds as a first-line treatment for hypertension, as well as a treatment of choice in diabetic patients with nephropathy. The recently published ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) study, performed in a vast population of individuals at high risk, has challenged this substantially exclusive indication of ACE inhibitors, and namely of ramipril, by testing the non-inferiority of the ARB telmisartan and the hypothesis of a superiority of the combination of ramipril plus telmisartan compared with monotherapy with ramipril alone. The results of this study demonstrated that telmisartan was substantially equivalent to ramipril in high-risk patients in terms of cardiovascular protection, while the combination of the two drugs was associated with more adverse events without an increase in cardiovascular benefit.",
keywords = "ACE inhibitors, Angiotensin II receptor blockers, Cardiovascular mortality, Cardiovascular risk, Clinical trials",
author = "Massimo Volpe",
year = "2008",
doi = "10.2165/00151642-200815020-00002",
language = "English",
volume = "15",
pages = "47--51",
journal = "High Blood Pressure and Cardiovascular Prevention",
issn = "1120-9879",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - A new option for therapeutic management of patients with cardiovascular disease

T2 - A closer look at the ONTARGET study

AU - Volpe, Massimo

PY - 2008

Y1 - 2008

N2 - Therapeutic strategy aimed at global cardiovascular risk reduction represents a key priority for any prevention strategy, as clearly stated in the most recent international guidelines. In this view, therapeutic strategies based on ACE inhibitors have been demonstrated to significantly reduce cardiovascular morbidity and mortality in high-risk individuals. In the last decade, a long debate has developed in the scientific and medical community over whether the newer classes of antihypertensive agents, such as angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), have additional properties beyond blood pressure control, and therefore are superior to ACE inhibitors in terms of cardiovascular prevention. ARBs have been extensively investigated in a number of clinical conditions across the whole continuum of cardiovascular renal diseases, and these studies have prompted the use of these compounds as a first-line treatment for hypertension, as well as a treatment of choice in diabetic patients with nephropathy. The recently published ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) study, performed in a vast population of individuals at high risk, has challenged this substantially exclusive indication of ACE inhibitors, and namely of ramipril, by testing the non-inferiority of the ARB telmisartan and the hypothesis of a superiority of the combination of ramipril plus telmisartan compared with monotherapy with ramipril alone. The results of this study demonstrated that telmisartan was substantially equivalent to ramipril in high-risk patients in terms of cardiovascular protection, while the combination of the two drugs was associated with more adverse events without an increase in cardiovascular benefit.

AB - Therapeutic strategy aimed at global cardiovascular risk reduction represents a key priority for any prevention strategy, as clearly stated in the most recent international guidelines. In this view, therapeutic strategies based on ACE inhibitors have been demonstrated to significantly reduce cardiovascular morbidity and mortality in high-risk individuals. In the last decade, a long debate has developed in the scientific and medical community over whether the newer classes of antihypertensive agents, such as angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), have additional properties beyond blood pressure control, and therefore are superior to ACE inhibitors in terms of cardiovascular prevention. ARBs have been extensively investigated in a number of clinical conditions across the whole continuum of cardiovascular renal diseases, and these studies have prompted the use of these compounds as a first-line treatment for hypertension, as well as a treatment of choice in diabetic patients with nephropathy. The recently published ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) study, performed in a vast population of individuals at high risk, has challenged this substantially exclusive indication of ACE inhibitors, and namely of ramipril, by testing the non-inferiority of the ARB telmisartan and the hypothesis of a superiority of the combination of ramipril plus telmisartan compared with monotherapy with ramipril alone. The results of this study demonstrated that telmisartan was substantially equivalent to ramipril in high-risk patients in terms of cardiovascular protection, while the combination of the two drugs was associated with more adverse events without an increase in cardiovascular benefit.

KW - ACE inhibitors

KW - Angiotensin II receptor blockers

KW - Cardiovascular mortality

KW - Cardiovascular risk

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=48449088563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48449088563&partnerID=8YFLogxK

U2 - 10.2165/00151642-200815020-00002

DO - 10.2165/00151642-200815020-00002

M3 - Article

C2 - 23334871

AN - SCOPUS:48449088563

VL - 15

SP - 47

EP - 51

JO - High Blood Pressure and Cardiovascular Prevention

JF - High Blood Pressure and Cardiovascular Prevention

SN - 1120-9879

IS - 2

ER -